- With a consistent presence in the CR Index for 16 years, GENESIS Pharma ranks among the most highly awarded companies in Greece for sustainable development.
GENESIS Pharma has been awarded the DIAMOND highest distinction for its performance in sustainable development for 2024-2025, based on the international ESG criteria, in the National Corporate Responsibility Index (CR Index) of the Corporate Responsibility Institute. GENESIS Pharma was the first pharmaceutical company to participate in this assessment back in 2009, and has continuously improved its performance ever since. Its ranking at the highest level of the Index, an achievement reached by only seven companies to date, reflects the company’s comprehensive strategic approach and the successful integration of sustainable development principles across its operations.
Through the CR Index, an internationally recognized benchmark for corporate responsibility, independent experts evaluate companies’ performance and their impact on society, the environment, the market, and their workforce. The assessment is based on international ESG criteria and standards aligned with global trends and European legislation on the integration of sustainability.
The CEO of GENESIS Pharma, Mr. Constantinos Evripides, stated: “Our goal is to improve the lives of people living with serious diseases by bringing international pharmaceutical innovation closer to them. This goal shapes the way we think and operate as a company, placing integrity, quality, and responsibility at the core of everything we do. We invest in operational excellence, in fostering a supportive work environment, in social contribution initiatives, and in environmental policies, with tangible results. We aim for our commitments and actions to have long-term impact. That is why we use performance models and indicators, such as the CR Index, which help us continuously improve. We are truly honored that our performance this year was recognized with the highest distinction, the DIAMOND award. We will continue with the same dedication, so that each day we can make a real, positive difference.”
A steadfast commitment to sustainability and social contribution
With nearly three decades of activity, GENESIS Pharma continues to evolve with a strong commitment to quality, excellence, and sustainability, while also implementing a wide range of social initiatives.
Aiming to ensure patient access to therapies of high-quality and safety, and to maintain transparency and scientific integrity in its collaboration with the healthcare sector, GENESIS Pharma invests in the commercialization of innovative and orphan medicines that address unmet medical needs, implements a comprehensive quality and safety policy, and upholds strict internal procedures to ensure regulatory and ethical compliance in line with the highest international standards. Another key priority is the implementation of a responsible environmental policy with measurable outcomes, as well as the cultivation of a good working environment recognized with numerous awards based on employee evaluations.
GENESIS Pharma’s social contribution program, spanning over two decades, is primarily focused on health-related issues. The company consistently supports the work of numerous patient associations and regularly undertakes awareness campaigns focused on health and prevention. At the same time, its activities extend to initiatives addressed to children and the young generation, with an emphasis on education, equal opportunities, fostering excellence, as well as promoting sports. Among these is the long-standing “Generous School” program that began fourteen years ago with the aim of providing computers and educational material to schools in remote islands and regions across Greece, as well as carrying out infrastructure upgrades and small-scale renovation projects at schools in the Attica region. More than 2,400 children in 26 remote regions have benefited from this program, while infrastructure upgrades have been carried out in 17 schools in Attica. With the same consistency, since 2015, the company has also been participating in the Program“DIATROFI” of the Prolepsis Institute, which addresses food insecurity among children. Through this initiative, 59,000 healthy meals have been offered to over 800 children in 16 schools. Lastly, the GENEROUS employee volunteer team plays a vital role in supporting numerous social organizations, while the company’s running team participates in athletic events in support of patient associations.
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales, and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical needs through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com or follow us on LinkedIn.
For more information, please contact:
Natalia Karahaliou, Communications Manager
nkarahaliou@genesispharma.com
+30 210 8771605